SHANGHAI, Jan. 8, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and Dexmethylphenidate Hydrochloride Capsules...
Hence then, the article about ark biopharmaceutical receives china marketing authorization for aizhida for the treatment of adhd was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD )
Also on site :
- GTA 6 dev Rockstar have seemingly been hacked again, but they don't seem all that worried
- 'Came here in good faith but ... ': JD Vance on why Iran peace talks failed
- Khoros lance Aurora AI : une nouvelle ère pour la communauté des entreprises